Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. develops and commercializes dialysis technology centered on the Tablo Hemodialysis System, an FDA-cleared platform used across hospital and home care settings. Company news commonly covers Tablo adoption, consumables and service revenue, product gross margin, cash use, and financial guidance tied to the company’s medical technology business.
Recurring updates also include FDA matters for the Tablo platform, including 510(k) clearance for a next-generation system with cybersecurity, reliability, and connectivity enhancements. Governance and compensation announcements include board changes, executive appointments, and inducement equity grants under Nasdaq rules.
Satellite Healthcare and Outset Medical (Nasdaq: OM) announced a multi-year sales agreement to enhance home hemodialysis adoption across Satellite Healthcare's dialysis centers. The agreement involves the purchase of Tablo systems for home use and collaboration on educational initiatives to increase patient awareness. Satellite Healthcare aims to lead in at-home dialysis treatment, serving over 8,000 patients annually. Factors such as Medicare Advantage eligibility and increased telehealth usage are expected to drive growth in home dialysis.
Outset Medical, Inc. (Nasdaq: OM), a medical technology innovator, announced its management's participation in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 7:30am PT / 10:30am ET. The event will be available via live and archived webcast on Outset's investors page. Outset's flagship product, the Tablo Hemodialysis System, offers a groundbreaking solution to streamline dialysis delivery, ensuring it can be provided anywhere and anytime, significantly enhancing patient care and reducing costs.
Outset Medical, Inc. (Nasdaq: OM) appoints Katie Szyman to its board of directors. With over 30 years of experience, Szyman has a proven track record in global medtech, significantly growing businesses at Edwards Lifesciences and Medtronic. As VP at Edwards, she increased critical care revenue by nearly 50% to $800M in six years. Szyman aims to help Outset accelerate its growth and transformation in dialysis care delivery. Outset’s innovative Tablo™ Hemodialysis System simplifies dialysis, making it accessible in various settings.
Outset Medical (Nasdaq:OM) has joined the Moving Health Home coalition, aimed at transforming home healthcare by influencing policy changes. This initiative highlights the importance of home-based care, especially post-COVID-19, allowing patients to manage chronic diseases at home. Outset's Tablo Hemodialysis System offers a compact, user-friendly solution for dialysis, enabling patients to reclaim their autonomy. The coalition's goal is to advocate for legislative support to enhance home healthcare access, aligning with Outset's mission to improve patient outcomes and reduce healthcare costs.
Outset Medical, Inc. (OM) reported a significant first quarter in 2021 with net revenues of $22.9 million, up 219% from the prior year. The Company achieved a gross margin of 1.3%, improving from a gross loss of (49.6%) in Q1 2020. Operating expenses rose to $30.0 million, resulting in a net loss of ($30.0 million) or ($0.70) per share. Positive news includes strong demand for its Tablo system, leading to an updated revenue guidance of $92 million to $97 million for 2021, reflecting an 84% to 94% growth.
Outset Medical, Inc. (Nasdaq: OM) will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 11:45am PT / 2:45pm ET. The event aims to discuss the company’s innovative dialysis technology, the Tablo Hemodialysis System, which simplifies dialysis treatment and enhances patient experience. A live and archived webcast will be available on Outset's website. This system allows for greater accessibility and efficiency in dialysis care, operating from hospital to home.
Outset Medical, Inc. (Nasdaq: OM) will announce its Q1 2021 financial results on May 5, 2021, after market close. A conference call with CEO Leslie Trigg and CFO Rebecca Chambers is scheduled for the same day at 2:00 PM PT (5:00 PM ET) to discuss these results. Outset is known for its innovative Tablo Hemodialysis System, designed to simplify dialysis treatment and reduce costs, allowing for flexibility in care delivery from hospitals to home settings.
Outset Medical, Inc. (Nasdaq: OM) announced the completion of its public offering, selling 2,945,864 shares at $53.50 each, alongside 3,890,723 shares from certain stockholders. The offering included 891,728 additional shares due to underwriter options, yielding net proceeds of approximately $149.7 million for Outset, after costs. The offering was managed by Morgan Stanley, BofA Securities, and Goldman Sachs, among others. Outset aims to leverage these funds for advancing its Tablo Hemodialysis System, which simplifies dialysis for patients and providers.
Outset Medical's Tablo Hemodialysis System has been awarded as one of seven winners in Round 2 of the KidneyX COVID-19 Kidney Care Challenge by the U.S. Department of Health and Human Services and the American Society of Nephrology. This recognition highlights Tablo's innovative solution for dialysis amid the pandemic, aimed at reducing transmission risks of COVID-19. With features like remote monitoring through TabloHub, Tablo simplifies dialysis, enhances patient care, and allows flexibility in resource management. The KidneyX Challenge has a total prize pool of $300,000 for innovative kidney care solutions.
Outset Medical, Inc. (Nasdaq: OM) has announced the pricing of a public offering of 2,500,000 shares of its common stock at $53.50 per share, alongside 3,444,859 shares sold by existing stockholders. Additionally, underwriters have a 30-day option to purchase up to 891,728 shares. The offering is set to close on April 13, 2021, subject to customary conditions. Morgan Stanley, BofA Securities, and Goldman Sachs are leading the underwriting effort. A registration statement related to this offering is effective with the SEC.